Search Options Stock News and Analysis from Schaeffer's

Bearish Bet on Pharma Stock Doubled Investors' Money

https://www.schaeffersresearch.com/content/options/2023/09/18/bearish-bet-on-pharma-stock-doubled-investors-money

9/18/2023 2:32 PM

Subscribers to Schaeffer's Leverage Trader service more than doubled their investment with our Bristol-Myers Squibb Co (NYSE:BMY) September 63 put recommendation, all in in just two weeks. Below, w...

Multiple Reasons to Keep Off This Pharma Stock

https://www.schaeffersresearch.com/content/analysis/2023/08/30/multiple-reasons-to-keep-off-this-pharma-stock

8/30/2023 1:42 PM

Bristol-Myers Squibb Co (NYSE:BMY) is down 0.7% to trade at $62.42 at last check, after the Biden administration included the pharmaceutical name's blood thinner Eliquis in its list of 10 prescriptio...

Pharmaceutical Stock Jumps on FDA Approval

https://www.schaeffersresearch.com/content/news/2022/09/12/pharmaceutical-stock-jumps-on-fda-approval

9/12/2022 10:23 AM

Bristol-Meyers Squibb Co (NYSE:BMY) is up 6.4% at $74.62 at last glance and earlier traded as high as $75.99, after the U.S. Food and Drug Administration (FDA) approved Sotyktu, the company's oral tre...

Red-Hot Bristol-Myers Squibb Stock Has Plenty of Room to Run

https://www.schaeffersresearch.com/content/options/2022/04/06/red-hot-drug-stock-has-room-to-run

4/6/2022 2:01 PM

The shares of Bristol-Myers Squibb Co (NYSE:BMY) have been on a steady uptrend over the last several months, while boasting low implied volatility (IV). What’s more, the sto...

BMY Looks to Launch Higher After Cancer Treatment Approval

https://www.schaeffersresearch.com/content/analysis/2021/06/30/bmy-looks-to-launch-higher-after-cancer-treatment-approval

6/30/2021 9:59 AM

Bristol-Myers Squibb Co (NYSE:BMY) is a global biopharmaceutical company that focuses on the discovery, development, and delivery of medications. The company manufactures prescription pharmaceuticals ...

PEOPLE ALSO SEARCH FOR